Transmembrane activator and CAML interactor (TACI) : another potential target for immunotherapy of multiple myeloma?

• المؤلفون الرئيسيون: Xu, Shengli, Lam, Kong-Peng
• مؤلفون آخرون: School of Biological Sciences
• التنسيق: مقال
• اللغة: English
• منشور في: 2021
• الموضوعات: Science::Biological sciences; TACI; Plasma Cell
• الوصول للمادة أونلاين: https://hdl.handle.net/10356/145955

Multiple myeloma (MM) has emerged as the next most likely oncological or hematological disease indication amenable for cellular immunotherapy. Much of the attention has been focused on B cell maturation antigen (BCMA) as a unique cell surface protein on myeloma cells that is available for monoclonal...